The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2024-0748
Date:	28-May-2025
Product Name:	SIMPONI (Golimumab), REMICADE (Infliximab), STELARA (Infliximab)
Therapeutic Area:	Immunology
Product Class:	Antirheumatic agents - biologic response modifiers
Condition(s) Studied:	Ulcerative Colitis
Protocol Number(s) and Title(s):	NCT00488631 - **C0524T18** A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy Administered Subcutaneously in Subjects With Moderately to severely Active Ulcerative Colitis NCT00036439 - **C0168T37** A Randomized Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of lnfliximab in Patients With Active Ulcerative Colitis NCT00096655 - **C0168T46** A Randomized Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of lnfliximab in Patients With Active Ulcerative Colitis NCT02407236 – **CNTO1275UCO3001** A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis NCT01369329 - **CNTO1275CRD3001** A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1) NCT01369342 - **CNTO1275CRD3002** A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2) NCT03464136 - **CNTO1275CRD3007** Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease

The YODA Project
Research Proposal Due Diligence Assessment

Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes
Part 4: Proposal Review	
Question:	**Response:**
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	Yes
Comments:	Yes to similar analysis for Ustekinumab